Traders should monitor future revenue guidance and test volume metrics in upcoming earnings; this approval positions Myriad for increased market penetration and potential pricing leverage. Consider long-term upside given exclusivity and alignment with standard-of-care treatment.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 18 $4.64entry
- T+1 · 8mo ago +2.37%α +2.64% · $4.75
- T+5 · 8mo ago +0.86%α +1.58% · $4.68
- T+20 · 7mo ago +7.76%α +1.71% · $5.00
- T+60 · 5mo ago −0.22%α −11.74% · $4.63
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Myriad Genetics announced FDA approval of its MyChoice® CDx Test as the companion diagnostic for GSK's Zejula (niraparib) in advanced ovarian cancer patients, based on the PRIMA trial data. This makes MyChoice CDx the only FDA-approved test in the U.S. to identify HRD-positive patients eligible for Zejula, reinforcing Myriad's leadership in ovarian cancer diagnostics and expanding the commercial utility of its test.
Key Facts
- FDA approved Myriad's MyChoice® CDx Test as the companion diagnostic for GSK's Zejula in advanced ovarian cancer.
- The approval is based on final data from the PRIMA trial, using HRD status to stratify patients.
- MyChoice CDx is now the only FDA-approved HRD test in the U.S. for PARP inhibitor eligibility with Zejula.
- The test identifies HRD status via comprehensive BRCA1/2 analysis and genomic instability score (GIS).
- Nearly 50% of advanced ovarian cancer patients have HRD-positive tumors, making this a significant patient population.
Financial Impact
Significant commercial upside potential, test now required for Zejula eligibility, likely increasing adoption and revenue. No direct dollar figure provided, but expands addressable market and strengthens pricing power.
Risk Factors
- Adoption dependent on physician uptake and payer reimbursement.
- Competition from lab-developed tests (LDTs) or future rival CDx approvals.
- Zejula's own market performance and safety profile could impact test utilization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257649 |
Track record
16 reports on MYGN
2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +13.54% at T+5 after the Oct 20, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry price pending
- Nov 9, 20267d ago 8-K Neutral 2/10 Entry $5.67 to $5.72 Now $5.57 −1.76% ▲ +0.88% −0.44% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $6.29 to $5.92 Now $5.57 −11.45% ▼ −5.88% −6.19% vs SPY
- Nov 4, 202612d ago 8-K Mixed 6/10 Entry $6.29 to $5.92 Now $5.57 −11.45% ▼ −5.88% −6.19% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $6.02 to $6.29 Now $5.57 −7.48% ▲ +4.49% +8.89% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $6.63 to $6.67 Now $5.57 −15.99% ▲ +0.60% +0.99% vs SPY
- Oct 20, 202627d ago 8-K Bullish 7/10 Entry $5.54 to $5.57 Now $5.57 +0.54% ▲ +0.54% +0.02% vs SPY
- Oct 15, 20264w ago Press Release Neutral 1/10 Entry $3.98 Now $5.57 +39.95% No price data
- Oct 9, 20265w ago 8-K Neutral 3/10 Entry $4.20 to $4.08 Now $5.57 +32.62% ▼ −2.86% −2.85% vs SPY
- Sep 16, 20268w ago 8-K Neutral 3/10 Entry $3.86 to $4.14 Now $5.57 +44.30% ▲ +7.25% +6.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers